Publications

5808 Results

Narrative review of developing new biomarkers for decision making in advanced testis cancer [Review]

Authors
L Nappi;C Nichols;C Kollmannsberger
Journal / Conference
Translational Andrology and Urology Oct;10(10):4075-4084
Year
2021
Research Committee(s)
Prevention, Screening, and and Surveillance
PMID
PMID34804849
PMC
PMC8575592
Study Number(s)
S1823

The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer [Editorial]

Authors
R Li;SP Lerner;A Kamat
Journal / Conference
European Urology Apr;79(4):437-439
Year
2021
Research Committee(s)
Genitourinary
PMID
PMID33454163
Study Number(s)
S1602, SWOG-8507

Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial

Authors
S Luger;V Wang;J Rowe;M Litzow;E Paietta;R Kettering;H Lazarus;W Rybka;M Craig;J Karp;B Cooper;A Makary;L Kaminer;F Appelbaum;R Larson;M Tallman
Journal / Conference
Leukemia Research Dec;111:106736
Year
2021
Research Committee(s)
Leukemia
PMID
PMID34773794
PMC
PMC8643322
Study Number(s)
CTSU/E2902

Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804

Authors
B McCormick;K Winter;W Woodward;H Kuerer;N Sneige;E Kakovitch;B Smith;I Germain;A Hartford;M O'Rourke;E Walker;E Strom;J Hopkins;L Pierce;A Pu;K Sumida;D Vesprini;J Moughan;J White
Journal / Conference
Journal of Clinical Oncology, Nov 10;39(32):3574-3582
Year
2021
Research Committee(s)
Breast
PMID
PMID34406870
PMC
PMC8577682
Study Number(s)
CTSU/R9804

Accounting for All Patients in Waterfall Plots

Authors
J Moon;M LeBlanc;M Othus
Journal / Conference
JCO Clinical Cancer Informatics Apr;5:414-420
Year
2021
Research Committee(s)
Melanoma
PMID
PMID33830787
PMC
PMC8240789
Study Number(s)
S0438, S0512

Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times

Authors
Z McCaw;A Odisho;H Chaparala;M Yin;J Cloyd;R Svatek;WE Carson;CT Lee;D Sundi
Journal / Conference
Urologic Oncology (Seminars and Original Investigations) Jul;39(7):435.e17-435.e22
Year
2021
Research Committee(s)
Genitourinary
PMID
PMID33436327
Study Number(s)
SWOG-8710 (INT-0080) (EST-1887) (CALGB-8891)

ESTIMATING RECURRENCE-FREE SURVIVAL OF NON-MUSCLE INVASIVE BLADDER CANCER AFTER INTRAVESICAL THERAPY: A CLINICAL-BASED RECURSIVE PARTITION ANALYSIS

Authors
N Corsi;E Messing;A Sood;J Keeley;C Bronkema;N Rakic;D Dalela;M Jamil;C Rogers;F Abdollah
Journal / Conference
Journal of Urology 2021;206(3):e304 - e304;
Year
2021
Research Committee(s)
Genitourinary
Study Number(s)
S0337

Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step towards Achieving Equity in Healthcare

Authors
Gormley N
Journal / Conference
Cancer Discov. 2021 Mar;2(2):119-124
Year
2021
Research Committee(s)
Cancer Care Delivery

Representativeness in Premarketing vs Postmarketing US Food and Drug Administration Trials

Authors
Unger JM
Journal / Conference
JAMA Netw Open. 2021 Apr 20;4(4):e217159
Year
2021
Research Committee(s)
Cancer Care Delivery

A Comparison of Oncologist versus Mental Health Provider Attitudes Towards Standardized and Tailored Patient-Reported Outcomes

Authors
Jones SMW
Journal / Conference
J Patient Rep Outcomes. 2021 Aug 24;5(1):76\
Year
2021
Research Committee(s)
Symptom Management and Survivorship